Treatment
Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial
Lung Cancer 2021 January 14 [Link] Sharyn I Katz, Leonid Roshkovan, Ian Berger, Joseph S Friedberg, Evan W Alley, Charles B Simone 2nd, Andrew R Haas, Keith A Cengel, Daniel H Sterman, Steven M Albelda Abstract Objectives: Soluble mesothelin-related protein (SMRP) and fibulin-3 serum levels may serve as diagnostic and prognostic biomarkers of malignant pleural…
Read MoreA novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20 : a case report and literature review
The Oncologist 2021 February 8 [Link] Chiho Miyagawa, Hisamitsu Takaya, Kazuko Sakai, Kazuto Nishio, Maho Konishi, Sachiko Minamiguchi, Toshihide Shimada, Noriomi Matsumura Abstract Recently, several malignant peritoneal mesothelioma (MPMs) that occur in young women without asbestos exposure and with fusion genes such as anaplastic lymphoma kinase (ALK) and Ewing sarcoma breakpoint region 1 (EWSR1) have…
Read MoreAlterations in BAP1 are Associated with Cisplatin Resistance Through Inhibition of Apoptosis in Malignant Pleural Mesothelioma (MPM)
Clinical Cancer Research 2021 February 5 [Link] Kathrin Oehl, Bart Vrugt, Ulrich Wagner, Michaela B Kirschner, Mayura Meerang, Walter Weder, Emanuela Felley-Bosco, Bernd Wollscheid, Katrin Bankov, Melanie C Demes, Isabelle Opitz, Peter J Wild Abstract Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of…
Read MoreMetformin Induces Apoptosis and Inhibits Notch1 in Malignant Pleural Mesothelioma Cells
Frontiers in Cell and Development Biology 2021 January 18 [Link] Marika Rossini, Fernanda Martini, Elena Torreggiani, Francesca Fortini, Giorgio Aquila, Francesco Vieceli Dalla Sega, Simone Patergnani, Paolo Pinton, Pio Maniscalco, Giorgio Cavallesco, Paola Rizzo, Mauro Tognon Abstract Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related cancer arising from the mesothelial cells lining the pleural cavity.…
Read MoreMalignant pleural mesothelioma in a patient with pneumothorax: A cumbersome subtype both clinically and pathologically
Thoracic Cancer 2021 February 2 [Link] Takafumi Fukui, Takako Okubo, Naoki Tanimoto, Hiromichi Okuma, Yoshitaka Shiina, Mizuki Kohama, Jun Yamada, Yasuhiro Funada, Yoshihiro Ikura Abstract Here, we report a case of malignant pleural mesothelioma (MPM) that was very difficult to diagnose. A 62-year-old woman with a surgical history of recurrent bilateral pneumothorax was admitted to…
Read MoreSwitch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
The Lancet Respiratory Medicine 2021 January 27 [Link] Cornedine J de Gooijer, Vincent van der Noort, Jos A Stigt, Paul Baas, Bonne Biesma, Robin Cornelissen, Nico van Walree, Robbert C van Heemst, Magdolen Youssef-El Soud, Harry J M Groen, Agnes J Staal-van den Brekel, Wieneke A Buikhuisen, Gerben P Bootsma, Floris Dammeijer, Harm van Tinteren,…
Read MoreClinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting
Acta Oncologica 2021 January 27 [Link] Thomas Ringgaard Petersen, Vasiliki Panou, Christos Meristoudis, Ulla Møller Weinreich, Oluf Dimitri Røe Abstract Background: This study aims to investigate patient- and disease characteristics associated with survival in malignant pleural mesothelioma (MPM) patients with anti-tumor treatment or with best supportive care (BSC). Materials and methods: Consecutive MPM cases diagnosed…
Read MoreRecurrence of mesothelioma after a macroscopic complete resection procedure: is a second radical surgery justified?
Interactive Cardiovascular and Thoracic Surgery 2021 January 26 [Link] Hany Hasan Elsayed, Aly Sherif Hassaballa, Taha Aly Ahmed, Hazem Youssef Sharkawy Abstract A best evidence topic was written according to a structured protocol. The question addressed was: In patients with mesothelioma who develop a local recurrence after macroscopic complete resection (MCR) surgery, does performing a…
Read MoreFirst-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Lancet 2021 January 21 [Link] Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jerónimo Rodríguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman Abstract Background: Approved systemic treatments…
Read MoreSurgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial
The Lancet Oncology 2021 January 12 [Link] B C John Cho, Laura Donahoe, Penelope A Bradbury, Natasha Leighl, Shaf Keshavjee, Andrew Hope, Prodipto Pal, Michael Cabanero, Kasia Czarnecka, Karen McRae, Ming-Sound Tsao, Marc de Perrot Abstract Background: A novel approach for managing malignant pleural mesothelioma, surgery for mesothelioma after radiotherapy (SMART), consisting of a short…
Read More